Designing Biomedical Stents for Vascular Therapy

Author(s):  
Arghya Paul

The breakthrough technologies of stent have revolutionized the medical industry, particularly in the field of percutaneous coronary interventions and other vascular therapies. However, recent concerns of late stent thrombosis and in-stent restenosis have rekindled an interest in developing new and improved therapeutic stent devices. A multidisciplinary approach of regeneration therapy, biomedicine, and nanotechnology is the next frontier for this. The chapter presented here gives a comprehensive overview of the evolving stent technologies for efficient vascular tissue therapy and articulates the potential of these technologies to design the next generation of therapeutic stent. In addition, the chapter also encompasses upcoming technologies to develop bioactive stents for efficient healing and remodeling of damaged local vascular biology.

2014 ◽  
pp. 972-996
Author(s):  
Arghya Paul

The breakthrough technologies of stent have revolutionized the medical industry, particularly in the field of percutaneous coronary interventions and other vascular therapies. However, recent concerns of late stent thrombosis and in-stent restenosis have rekindled an interest in developing new and improved therapeutic stent devices. A multidisciplinary approach of regeneration therapy, biomedicine, and nanotechnology is the next frontier for this. The chapter presented here gives a comprehensive overview of the evolving stent technologies for efficient vascular tissue therapy and articulates the potential of these technologies to design the next generation of therapeutic stent. In addition, the chapter also encompasses upcoming technologies to develop bioactive stents for efficient healing and remodeling of damaged local vascular biology.


2020 ◽  
Vol 10 (2) ◽  
Author(s):  
Huda Hamid ◽  
John Coltart

Over the last three decades, percutaneous coronary intervention (PCI) technology has revolutionized the field of cardiology. PCI began in the form of balloon angioplasty, and was followed by coronary stenting. In-Stent restenosis is the main limitation of coronary stenting, and has been delayed to some extent by the development of drug eluting stents. Coronary angioplasty with stenting is currently the most popular non-medical treatment of coronary artery disease therefore solving the problem of in-stent restenosis could change the future role of other types of coronary intervention. This review examines the types of percutaneous coronary interventions, the mechanisms leading up to in-stent restenosis, and how previous and current treatments of in-stent restenosis influence the vascular response to injury.


Author(s):  
К.Б. Богатырева ◽  
М.М. Азова ◽  
З.Х. Шугушев ◽  
Аисса А. Аит ◽  
А.В. Агаджанян ◽  
...  

В настоящее время рестеноз является основной проблемой, возникающей после чрескожных коронарных вмешательств. К причинам повторного сужения артерии после стентирования относятся клинические, ангиографические и генетические факторы. В представленной работе изучены некоторые полиморфные локусы генов ренин-ангиотензин-альдостероновой системы, фолатного цикла и эндотелиальной синтазы оксида азота. Выявлены генетические варианты, ассоциированные с рестенозом, развивающимся в различные сроки после стентирования (до 6 месяцев или позже). Currently, restenosis is a major challenge arising after percutaneous coronary interventions. Causes of re-narrowing of the artery after stenting include clinical, angiographic, and genetic factors. Some polymorphic loci of the renin-angiotensin-aldosterone system, folate cycle, and endothelial nitric oxide synthase genes have been studied. Genetic variants associated with the restenosis developing at different time periods after stent implantation (within the first 6 months or later) have been identified.


Sign in / Sign up

Export Citation Format

Share Document